|
Friday, June 2, 2023, Chicago, Illinois, 6:30 PM – 9:00 PM Central Time (7:30 PM – 10:00 PM Eastern Time)
Video Consensus or Controversy? Clinical Investigators Provide Perspectives on the Current and Future Management of Non-Small Cell Lung CancerA CME Hybrid Symposium Held in Conjunction with the 2023 ASCO Annual Meeting
Location
Hilton Chicago 720 South Michigan Avenue Chicago, IL 60605 Phone: (312) 922-4400 Program Schedule — Central Time 6:00 PM – 6:30 PM — Registration and Dinner 6:30 PM – 9:00 PM — Educational Meeting Meeting Room Grand Ballroom (Level 2) This event will also be webcast live. Please see Registration tab for details. Faculty
Edward B Garon, MD, MS Professor Director, Thoracic Oncology Program Director, Signal Transduction and Therapeutics Research Program David Geffen School of Medicine at UCLA Jonsson Comprehensive Cancer Center Los Angeles, California John V Heymach, MD, PhD Professor and Chair Thoracic/Head and Neck Medical Oncology The University of Texas MD Anderson Cancer Center Houston, Texas Corey J Langer, MD Director of Thoracic Oncology Abramson Cancer Center Professor of Medicine Perelman School of Medicine University of Pennsylvania Philadelphia, Pennsylvania Ticiana Leal, MD Associate Professor Department of Hematology and Oncology Director, Thoracic Medical Oncology Winship Cancer Institute Emory University Atlanta, Georgia David R Spigel, MD Chief Scientific Officer Sarah Cannon Research Institute Nashville, Tennessee Helena Yu, MD Medical Oncologist Associate Attending Memorial Sloan Kettering Cancer Center New York, New York Moderator Neil Love, MD Research To Practice Miami, Florida This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Lilly, Novocure Inc, Regeneron Pharmaceuticals Inc, and Takeda Pharmaceuticals USA Inc.
Program Schedule — Central Time 6:00 PM – 6:30 PM — Registration and Dinner Buffet 6:30 PM – 9:00 PM — Educational Meeting MODULE 1: Incorporation of Immunotherapeutic Strategies into the Management of Nonmetastatic Non-Small Cell Lung Cancer (NSCLC) — Dr Heymach
MODULE 2: Contemporary Treatment for Localized or Metastatic NSCLC with an EGFR Mutation — Dr Yu
MODULE 3: Research Advances Shaping the Current and Future Treatment of Metastatic NSCLC with ALK Rearrangements, ROS1 Rearrangements or RET Fusions — Dr Langer
MODULE 4: Targeting MET, HER2 and KRAS Alterations in NSCLC — Dr Spigel
MODULE 5: Current Management of Metastatic NSCLC without a Targetable Tumor Mutation — Dr Garon
MODULE 6: Future Directions in the Management of Metastatic NSCLC — Dr Leal
Target Audience
CME Credit Form FACULTY — The following faculty reported relevant financial relationships with ineligible entities: Dr Garon — Consulting Agreements: ABL Bio, AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Dracen Pharmaceuticals, Eisai Inc, EMD Serono Inc, Gilead Sciences Inc, GSK, Lilly, Merck, Natera Inc, Novartis, Personalis, Regeneron Pharmaceuticals Inc, Sanofi, Shionogi Inc, Xilio Therapeutics, Zymeworks Inc; Contracted Research: ABL Bio, AstraZeneca Pharmaceuticals LP, BioNTech SE, Bristol Myers Squibb, Daiichi Sankyo Inc, Dynavax Technologies, EMD Serono Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, lovance Biotherapeutics, Lilly, Merck, Mirati Therapeutics Inc, Novartis; Data and Safety Monitoring Board/Committee: Nuvalent; Sponsored Independent Medical Education: Daiichi Sankyo Inc, Ipsen Biopharmaceuticals Inc; Travel: A2 Bio, Novartis. Dr Heymach — Advisory Committee: AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim Pharmaceuticals Inc, BrightPath Biotherapeutics Co Ltd, Bristol Myers Squibb, Catalyst Pharmaceuticals, Chugai Pharmaceutical Co Ltd, EMD Serono Inc, Genentech, a member of the Roche Group, GSK, Hengrui Therapeutics Inc, Janssen Biotech Inc, Lilly, Mirati Therapeutics Inc, Nexus Health Systems, Pneuma Respiratory, RefleXion, Sanofi, Spectrum Pharmaceuticals Inc, Takeda Pharmaceuticals USA Inc; Research Support: AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim Pharmaceuticals Inc, Spectrum Pharmaceuticals Inc, Takeda Pharmaceuticals USA Inc; Royalties and Licensing Fees: Spectrum Pharmaceuticals Inc. Dr Langer — Consulting Fees: AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim Pharmaceuticals Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, GSK, Heat Biologics, Merck, Mirati Therapeutics Inc, Novocure Inc, Pfizer Inc, Regeneron Pharmaceuticals Inc, Sanofi, Takeda Pharmaceuticals USA Inc; Data Safety Monitoring Board or Advisory Board (Co-Chair): Amgen Inc, Oncocyte; Medical Writing: Novartis; Research Funding: AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim Pharmaceuticals Inc, Inovio Pharmaceuticals Inc, Lilly, Merck, Oncocyte, Takeda Pharmaceuticals USA Inc, Trizell; Nonrelevant Financial Relationship: US Department of Veterans Affairs. Dr Leal — Consultant/Advisory Boards: Amgen Inc, AstraZeneca Pharmaceuticals LP, Catalyst Pharmaceuticals, Daiichi Sankyo Inc, Eisai Inc, EMD Serono Inc, Janssen Biotech Inc, Jazz Pharmaceuticals Inc, Merck, Novocure Inc, Regeneron Pharmaceuticals Inc, Roche Laboratories Inc, Takeda Pharmaceuticals USA Inc; Contracted Research: Advaxis Inc, Bayer HealthCare Pharmaceuticals, Pfizer Inc; Data and Safety Monitoring Board/Committee: OncoC4; Speaker: Aptitude Health, Cardinal Health, Curio Bioscience; Nonrelevant Financial Relationship: ASTRO, GASCO, GRACE, IDEOlogy Health, Medscape, National Cancer Institute, Nebraska Oncology Society, OncLive, Opinions in Lung Cancer, PeerView, SITC, Targeted Oncology. Dr Spigel — Consulting Agreements (to Institution): Amgen Inc, AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Curio Science, EMD Serono Inc, Evidera, Exelixis Inc, Genentech, a member of the Roche Group, GSK, Intellisphere LLC, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, Jazz Pharmaceuticals Inc, Lilly, Mirati Therapeutics Inc, Molecular Templates, Novartis, Novocure Inc, Pfizer Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi; Contracted Research (to Institution): Aeglea BioTherapeutics, Agios Pharmaceuticals Inc, Apollomics Inc, Arcus Biosciences, Arrys Therapeutics, a wholly owned subsidiary of Kyn Therapeutics, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BIND Therapeutics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Calithera Biosciences, Celgene Corporation, Celldex Therapeutics, Clovis Oncology, Cyteir Therapeutics, Daiichi Sankyo Inc, Denovo Biopharma, Eisai Inc, Elevation Oncology, EMD Serono Inc, Evelo Biosciences Inc, G1 Therapeutics Inc, Genentech, a member of the Roche Group, GSK, Grail Inc, Hutchison MediPharma, ImClone Systems, a wholly owned subsidiary of Eli Lilly and Company, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, Kronos Bio, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, MacroGenics Inc, Merck, Molecular Partners, Molecular Templates, Nektar, Neon Therapeutics, Novartis, Novocure Inc, OncXerna Therapeutics Inc, Pfizer Inc, PTC Therapeutics, PureTech Health, Razor Genomics, Repare Therapeutics, Rgenix, Takeda Pharmaceuticals USA Inc, Tesaro, A GSK Company, Tizona Therapeutics Inc, Transgene, UT Southwestern Medical Center, Verastem Inc. Dr Yu — Consulting Agreements: AbbVie Inc, AstraZeneca Pharmaceuticals LP, Black Diamond Therapeutics Inc, Blueprint Medicines, C4 Therapeutics, Cullinan Oncology, Daiichi Sankyo Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, Takeda Pharmaceuticals USA Inc; Data and Safety Monitoring Board/Committee: Janssen Biotech Inc; Research Funding to My Institution: AstraZeneca Pharmaceuticals LP, Black Diamond Therapeutics Inc, Blueprint Medicines, Cullinan Oncology, Daiichi Sankyo Inc, Erasca, Janssen Biotech Inc, Novartis, Pfizer Inc.CONTRIBUTING INVESTIGATORS — Matthew Gubens, MD, MS — Consulting Agreements: AnHeart Therapeutics, AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Cardinal Health, Genentech, a member of the Roche Group, Genzyme Corporation, Gilead Sciences Inc, Guardant Health, iTeos Therapeutics, Sanofi, Summit Therapeutics, Surface Oncology; Contracted Research (Funding to Institution as Site PI): Amgen Inc, Celgene Corporation, Johnson & Johnson Pharmaceuticals, Merck, Novartis, OncoMed Pharmaceuticals Inc, Trizell. Melissa Johnson, MD — Consulting Agreements: AbbVie Inc, Amgen Inc, Arcus Biosciences, ArriVent Biopharma, Astellas, AstraZeneca Pharmaceuticals LP, Axelia Oncology, Black Diamond Therapeutics Inc, Calithera Biosciences, Daiichi Sankyo Inc, EcoR1 Capital LLC, Genentech, a member of the Roche Group, Genmab US Inc, Genocea, Gritstone bio, GSK, IDEAYA Biosciences, Immunocore, iTeos Therapeutics, Janssen Biotech Inc, Jazz Pharmaceuticals Inc, Merck, Mirati Therapeutics Inc, Molecular Axiom, Novartis, Oncorus, Pyramid Biosciences, Regeneron Pharmaceuticals Inc, Revolution Medicines, Sanofi, Seagen Inc, Synthekine, Takeda Pharmaceuticals USA Inc, Turning Point Therapeutics Inc, VBL Therapeutics; Contracted Research: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Adaptimmune, Amgen Inc, Apexigen, Arcus Biosciences, Array BioPharma Inc, a subsidiary of Pfizer Inc, AstraZeneca Pharmaceuticals LP, Atreca, BeiGene Ltd, BerGenBio ASA, BioAtla, Birdie Biopharmaceuticals, Black Diamond Therapeutics Inc, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Calithera Biosciences, Carisma Therapeutics, Checkpoint Therapeutics Inc, Corvus Pharmaceuticals, Curis Inc, CytomX Therapeutics, Daiichi Sankyo Inc, Dracen Pharmaceuticals, Dynavax Technologies, Elicio Therapeutics, EMD Serono Inc, EQRx, Erasca, Exelixis Inc, Fate Therapeutics, Genentech, a member of the Roche Group, Genmab US Inc, Genocea, Gritstone bio, GSK, Guardant Health, Harpoon Therapeutics, Helsinn Healthcare SA, Hengrui Therapeutics Inc, Hutchison MediPharma, IDEAYA Biosciences, Immunitas Therapeutics, Immunocore, Incyte Corporation, Janssen Biotech Inc, Jounce Therapeutics, Kadmon, Kartos Therapeutics, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Lycera, Merck, Merus BV, Mirati Therapeutics Inc, Mythic Therapeutics, NeolummuneTech, Neovia Oncology, Novartis, Nuvalent, OncoMed Pharmaceuticals Inc, Palleon Pharmaceuticals, Pfizer Inc, PMV Pharma, Rain Therapeutics, Rascal Therapeutics, Regeneron Pharmaceuticals Inc, Relay Therapeutics, Revolution Medicines, Ribon Therapeutics, Roivant Sciences Ltd, Rubius Therapeutics, Sanofi, Seven and Eight Biopharmaceuticals Inc, Shattuck Labs, Stemcentrx, Syndax Pharmaceuticals Inc, Takeda Pharmaceuticals USA Inc, Tarveda Therapeutics, TCR2 Therapeutics, Tempest Therapeutics, Tizona Therapeutics Inc, Tmunity Therapeutics, Turning Point Therapeutics Inc, Vyriad, WindMIL Therapeutics, Y-mAbs Therapeutics Inc; Nonrelevant Financial Relationship: City of Hope National Medical Center, Memorial Sloan Kettering Cancer Center, University of Michigan. Jarushka Naidoo, MB BCH, MHS — Advisory Committee and Consulting Agreements: AbbVie Inc, Amgen Inc, Arcus Biosciences, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Bristol Myers Squibb, Daiichi Sankyo Inc, Elevation Oncology, Genentech, a member of the Roche Group, Kaleido Biosciences, Mirati Therapeutics Inc, NGM Biopharmaceuticals, Pfizer Inc, Regeneron Pharmaceuticals Inc, Takeda Pharmaceuticals USA Inc; Contracted Research: Amgen Inc, Arcus Biosciences, AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Genentech, a member of the Roche Group, Mirati Therapeutics Inc, Pfizer Inc, Takeda Pharmaceuticals USA Inc; Data and Safety Monitoring Board/Committee: Bristol Myers Squibb, Daiichi Sankyo Inc. MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Celgene Corporation, Clovis Oncology, Coherus BioSciences, CTI BioPharma Corp, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences Corporation, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab US Inc, Gilead Sciences Inc, Grail Inc, GSK, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Kronos Bio Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc, Verastem Inc, and Zymeworks Inc. Research To Practice CME Planning Committee Members, Staff and Reviewers — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose. SupportersThis activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Lilly, Novocure Inc, Regeneron Pharmaceuticals Inc, and Takeda Pharmaceuticals USA Inc. Hilton Chicago
This activity is intended for medical and radiation oncologists, hematologists, hematology-oncology fellows, surgeons and other healthcare providers involved in the treatment of lung cancer. IN-PERSON registration
Thank you for your interest in our CME program taking place in Chicago, IL. At this time online in-person preregistration is closed for this event. SEATS ARE STILL AVAILABLE FOR THE PROGRAM AND WILL BE OFFERED ON A FIRST COME FIRST SERVCE BASIS. Our Onsite Registration Desk will be open at 6:00 PM Central Time on Friday, June 2. If you are interested in attending, please visit our registration desk located outside the Grand Ballroom (Level 2) of the Hilton Chicago hotel (720 South Michigan Avenue). ASCO offers complimentary shuttle service from the McCormick Place Convention Center to this hotel. Information on shuttle service is available on the 2023 ASCO Annual Meeting website. Please note: onsite registration does not guarantee meal service which will be based on availability.
If you have any questions, please feel free to contact us via email at Meetings@ResearchToPractice.com, or call (800) 233-6153. Registration for live webcast
Please note we will stream this event over Zoom. After registering you will receive a separate confirmation from Zoom with the viewing instructions. Registration for Webcast »Registration for groups
If you are registering a group (more than 1 person) for this event, please contact us at
Meetings@ResearchToPractice.com or (800) 233-6153.
To ensure seating and meal service, please check in at our onsite registration desk at least 30 minutes before the start of the meeting. We cannot guarantee seating after the start of the program.Photography and/or video recording may be taken during the educational program by Research To Practice and used in future educational offerings. Research To Practice fully complies with the legal requirements of the ADA. If you are in need of assistance (ie, physical, dietary, et cetera), please contact us prior to the event at (800) 233-6153.
Not an official event of the 2023 ASCO Annual Meeting. Not sponsored, endorsed, or accredited by ASCO®, Association for Clinical Oncology, CancerLinQ®, or Conquer Cancer®, the ASCO Foundation. |